title: [Molecular targeting therapy in rheumatoid arthritis].
authors.forename: Toru
authors.initials: T
authors.lastname: Mima
authors.forename: Yuri
authors.initials: Y
authors.lastname: Nakashima
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Hanba
authors.forename: Masaki
authors.initials: M
authors.lastname: Ohya
authors.forename: Shigeo
authors.initials: S
authors.lastname: Negi
authors.forename: Takashi
authors.initials: T
authors.lastname: Shigematsu
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD / Q000276:immunology*; D018951:Antigens, CD20 / Q000276:immunology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000209:etiology; D001402:B-Lymphocytes; D006801:Humans; D007375:Interleukin-1; D015850:Interleukin-6; D020929:Mitogen-Activated Protein Kinase Kinases; D058990:Molecular Targeted Therapy; D010010:Osteoclasts; D000069283:Rituximab; D015398:Signal Transduction / Q000235:genetics; D013601:T-Lymphocytes; D014409:Tumor Necrosis Factor-alpha
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD; D018951:Antigens, CD20; D007375:Interleukin-1; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab; D020929:Mitogen-Activated Protein Kinase Kinases